Protection of Intellectual Property (IP) in Synthetic Biology and Engineered Organism Design

Synthetic biology and engineered organisms sit at the intersection of biotechnology, genetics, and engineering. Because these inventions involve living systems, IP protection becomes complex: courts must balance innovation incentives with ethical limits on owning life.

IP protection mainly operates through:

• Patents (most important in biotech)
• Trade secrets (e.g., proprietary gene-editing methods)
• Regulatory exclusivity (biologics data protection in some jurisdictions)

The biggest legal tension is: Can life forms, genes, or engineered organisms be owned or patented?

Below are leading case laws (US, Canada, EU) that shape this field.

1. Diamond v. Chakrabarty (1980, United States)

Facts:

Ananda Chakrabarty, a scientist working for General Electric, genetically engineered a bacterium (Pseudomonas) capable of breaking down crude oil. He applied for a patent on:

• The genetically modified bacterium
• The process of creating it

The US Patent Office rejected it, arguing that living organisms are not patentable.

Issue:

Can a genetically modified living organism be patented?

Decision:

The US Supreme Court ruled YES, allowing the patent.

Reasoning:

• The organism was not naturally occurring
• It was a product of human ingenuity
• Patent law covers “anything under the sun made by man”

Impact on Synthetic Biology:

This is the foundation case for biotech patents. It established that:

• Engineered microorganisms are patentable
• Synthetic biology organisms can be protected if they are “human-made”

👉 Without this case, synthetic biology patents would largely not exist.

2. Association for Molecular Pathology v. Myriad Genetics (2013, United States)

Facts:

Myriad Genetics discovered the precise location and sequence of BRCA1 and BRCA2 genes, linked to breast and ovarian cancer. They obtained patents on:

• Isolated DNA sequences
• Diagnostic testing methods

They sued labs performing similar genetic tests.

Issue:

Are human genes patentable if isolated from the body?

Decision:

The Supreme Court ruled:

• Naturally occurring DNA cannot be patented
• But synthetically created cDNA (complementary DNA) can be patented

Reasoning:

• Discovery ≠ invention
• Isolating a gene does not make it “new”
• However, cDNA is lab-made and not naturally occurring

Impact:

This case is critical in synthetic biology because it:

• Removes monopoly over natural genetic sequences
• Still protects engineered genetic constructs

👉 Synthetic biology shifted toward designing modified or artificial sequences instead of isolating natural ones.

3. Mayo Collaborative Services v. Prometheus Laboratories (2012, United States)

Facts:

Prometheus patented a method for optimizing drug dosage based on metabolite levels in blood.

Doctors using the test were sued for infringement.

Issue:

Can a natural biological correlation be patented?

Decision:

The Supreme Court ruled NO, invalidating the patents.

Reasoning:

• The correlation between drug metabolite levels and health outcomes is a natural law
• Adding routine lab steps is not enough to make it patentable

Impact on Synthetic Biology:

This case tightened biotech patent standards:

• You cannot patent natural biological relationships
• You must add a real inventive concept

👉 This directly affects synthetic biology diagnostics and biosensors.

4. Monsanto Canada Inc. v. Schmeiser (2004, Supreme Court of Canada)

Facts:

Farmer Percy Schmeiser’s crops contained genetically modified Roundup Ready canola patented by Monsanto. He claimed:

• The seeds blew into his fields accidentally
• He did not intentionally plant them

Monsanto sued for patent infringement.

Issue:

Can patent rights be enforced over self-replicating living organisms found on a farm?

Decision:

The court ruled in favor of Monsanto.

Reasoning:

• Even unintentional possession can constitute use
• Schmeiser benefited economically by saving seeds
• Patent protection extends to replicating organisms

Impact:

This case is extremely important for synthetic biology because:

• Engineered organisms are treated like self-replicating patented machines
• Raises concerns about contamination liability

👉 It strengthens corporate control over genetically engineered crops.

5. Monsanto Co. v. Bowman (2013, United States Supreme Court)

Facts:

Farmer Bowman purchased soybeans from a grain elevator (meant for consumption), planted them, and they grew into Monsanto’s patented Roundup Ready soybeans.

Issue:

Does patent exhaustion allow reuse of patented seeds?

Decision:

Court ruled NO in favor of Monsanto.

Reasoning:

• Patent exhaustion applies to sold items, but not to replication
• Seeds reproduce themselves; each generation is a new copy
• Unauthorized planting = making a new patented product

Impact:

This is crucial in engineered organism IP:

• Protects self-replicating synthetic biology systems
• Prevents unauthorized propagation of engineered traits

👉 It effectively extends patent control across generations of organisms.

6. J.E.M. Ag Supply v. Pioneer Hi-Bred International (2001, United States)

Facts:

The issue was whether sexually reproduced plants (hybrid corn seeds) could be patented.

Issue:

Are plants eligible for utility patents, or only special plant protection laws apply?

Decision:

Supreme Court ruled plants are patentable under utility patents.

Reasoning:

• Patent Act is broad enough to include plants
• Plant-specific protection laws do not exclude utility patents

Impact:

This case expanded biotech IP coverage:

• Both traditional breeding and genetic engineering can be patented
• Supports commercialization of engineered crops

7. Harvard “OncoMouse” Case (EPO decision T 19/90, Europe)

Facts:

Harvard University developed a genetically engineered mouse susceptible to cancer for research purposes (“OncoMouse”).

Issue:

Can higher animals genetically modified for research be patented in Europe?

Decision:

• Initially controversial; eventually granted with restrictions
• Allowed patenting but with ethical balancing under morality rules

Reasoning:

• Must balance industrial applicability with animal suffering
• Allowed because of strong medical benefits

Impact on Synthetic Biology:

• Europe allows biotech patents but applies ethical restrictions
• Synthetic organisms involving animals face stricter scrutiny than microbes

Overall Legal Principles from These Cases

1. Patentability of Life Forms

• Allowed if human-made and non-natural (Chakrabarty)
• Not allowed if naturally occurring genetic material (Myriad)

2. Functional vs Natural Distinction

• Natural biological laws cannot be patented (Mayo)
• Engineered functions can be protected

3. Self-Replication Doctrine

• Engineered organisms remain protected even when they replicate (Bowman, Schmeiser)

4. Ethical and Policy Constraints

• EU applies morality and animal welfare tests (OncoMouse)
• US focuses more on innovation and market incentives

Conclusion

IP protection in synthetic biology is built on a careful legal balance:

• Encourage innovation in genetic engineering
• Prevent monopolization of natural life and genes
• Control risks of self-replicating patented organisms

Together, these cases define a global framework where:

Genes as discovered → not patentable
Engineered biological systems → patentable
Natural biological laws → not patentable
Engineered applications → often patentable